Cavidi AB is a pharmaceutical company based in Uppsala, specializing in advanced diagnostic solutions. The company is recognized for its ultra-sensitive detection capabilities, which allow for the identification of low-abundance biomarkers. This technology is particularly beneficial in various medical fields, including cardiology and neuroscience, where accurate biomarker detection is crucial for early diagnosis and treatment.
One of the notable features of Cavidi's offerings is the BOLD signal amplification process, which significantly enhances the detection of specific biomarkers. For instance, it improves the detection of cardiac troponin I by 180 times and boosts IL-4 detection by 50 times. These advancements contribute to improved diagnostic accuracy and efficiency, making it easier for healthcare professionals to gain insights into cardiac conditions and other health issues.
Cavidi also provides standard immunoassay workflows compatibility, ensuring that their products can be integrated into existing laboratory processes. The company offers Exazym® test kits, which can be ordered online, facilitating access to their innovative diagnostic tools. Overall, Cavidi AB focuses on enhancing the capabilities of biomarker detection methods to support research and clinical applications.